Background In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug ibrutinib. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as "the company"). The dossier was sent to IQWiG on 1 February 2016.
http://ift.tt/2zb657e
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου